•  
  •  
  •  
  •  

2025-12-05 23:53:17

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Supreme Petrochem Ltd announces temporary closure of plant at Manali, Chennai
  • Quess Corp elevates Lohit Bhatia to CEO to lead next phase of growth
  • ACS Technologies Ltd receives order worth Rs. 5.39 crore
  • Reliance Infrastructure clarifies that majority of assets attached by ED pertains to RCOM, company operating normally
  • BMW Ventures Ltd secures order worth Rs. 6.02 crore

Keywords Selected:  LifeSciences

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Zydus receives EIR for the injectable facility located at Jarod
  • Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP
  • Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
  • Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Eris Lifesciences to consolidate its stake in Swiss Parenterals
  • SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Zydus' Amplitude receives CE mark for its robotic surgical system 'Andy'
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore
  • Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad
  • Zydus receives approval from Health Canada for Mesalamine suppositories
  • Advagen Holdings Inc. to acquire stake in GEn1E Lifesciences Inc.
  • RPG Life Sciences Ltd Q2 FY2026 PAT surges to Rs. 36.85 crores
  • Indegene Strengthens Consulting Practice to Accelerate Life Sciences Transformation
  • Sai Life Sciences, Agility Life Sciences, and Centrix Pharma announce an 'Integrated CMC Partnership' to accelerate drug development for innovators
  • Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • Sentynl Therapeutics updates on its NDA for CUTX-101

Latest Post

  • Supreme Petrochem Ltd announces temporary closure of plant at Manali, Chennai
  • Quess Corp elevates Lohit Bhatia to CEO to lead next phase of growth
  • ACS Technologies Ltd receives order worth Rs. 5.39 crore
  • Reliance Infrastructure clarifies that majority of assets attached by ED pertains to RCOM, company operating normally
  • BMW Ventures Ltd secures order worth Rs. 6.02 crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024